Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28520747 | 0.97 | TSHR (0.43) | TSHRALDH1A1CA12CA1CA2 | |
| Boric Acid SCHEMBL27917268 | 0.90 | TSHR (0.35) | TSHRALDH1A1 | |
| SCHEMBL6718168 | 0.90 | TSHR (0.46) | TSHRALDH1A1CA2 | |
| SCHEMBL7983058 | 0.89 | — | — | |
| SCHEMBL30818337 | 0.86 | LMNA (0.46) | TSHR | |
| SCHEMBL21373707 | 0.85 | — | — | |
| SCHEMBL21373708 | 0.85 | — | — | |
| SCHEMBL13890633 | 0.84 | TSHR (0.36) | TSHR | |
| SCHEMBL27999858 | 0.83 | TSHR (0.34) | TSHR | |
| SCHEMBL366646 | 0.81 | TSHR (0.48) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113841281-A | Electrolyte solution, electrochemical device, and electronic device | 宁德新能源科技有限公司 | 2021-12-24 | — | — | CN | claimed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-113841281-A | Electrolyte solution, electrochemical device, and electronic device | 宁德新能源科技有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-7557111-B2 | Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070254898-A1 | Thienopyrimidine and Thienopyridine Derivatives Substituted with Cyclic Amino Group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-4246282-A | ω-Dialkylalkanoic acid derivatives used to induce antianoxic activity | LABAZ (FR) | 1981-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254898-A1 | Thienopyrimidine and Thienopyridine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH3, HRH4 | TSHR 125/4885ALDH1A1 3445/4885CA12 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.